Total Funding
62
72
Total FundingGrant raised
Growth Score
-4 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
95194
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic.
- E. Russell McAllister: Chief Executive Officer & President
About the Company
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a ruthenium-based small molecule therapeutic, improves the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and
proliferation pathway.
Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
